The Greenfield-based unit, which makes a vast array of vaccines, antibiotics, feed additives and other health products for livestock and pets, is in a slump, after more than a decade of growth.
Indianapolis-based pharmaceutical giant Eli Lilly and Co. said the 3,500 jobs represent 8.3 percent of its global workforce. Lilly hopes the cuts will save it $500 million a year.
Danish drugmaker Novo Nordisk says it has reached a settlement over allegations that it hadn’t properly communicated safety information when marketing a medicine to treat type 2 diabetes.
The Indianapolis drugmaker said it will not be required to conduct another expensive, time-consuming clinical trial for the potential blockbuster.
Over the past 20 years, while the price of a gallon of milk climbed 23 percent and the sticker on a Dodge Caravan minivan rose 21 percent, the list price of the insulin Humalog shot up 1,157 percent.
President Donald Trump criticized drug prices immediately after Merck & Co.’s CEO quit the president’s council of manufacturing executives Monday, to take a “stand against intolerance and extremism.”
Global pharmaceutical companies including Indianapolis-based Eli Lilly and Co. are heading into smaller cities and rural areas to learn about the health care needs of about 70 percent of India’s population.
The deal is Eli Lilly and Co.’s latest push into a growing disease area for such disorders as arthritis, lupus and multiple sclerosis.
Drugmakers like Eli Lilly and Co. plunged off a patent cliff earlier this decade, losing billions in sales as lucrative branded drugs lost exclusivity. An expensive lobbying effort aimed at preventing a repeat is paying off.
Britain's Supreme Court has ruled in favor of Eli Lilly and Co. in a patent dispute with generic drugmaker Actavis over Lilly's Alimta cancer treatment.
The new sites are located at health centers in Johnson, Allen, Vigo, Monroe and Tippecanoe counties, the Indiana Family and Social Services Administration announced Wednesday morning.
Noblesville-based Pharmakon had a history of making state and local incentive agreements before suspending operations last year after a Food and Drug Administration investigation uncovered safety issues and possible criminal activity.
The co-owner of a pharmacy responsible for the deaths of 76 people was sentenced Monday to nine years in prison. Indiana was one of the state hit hardest by the 2012 nationwide fungal meningitis outbreak.
As medicines—especially those that treat conditions such as anxiety or depression—are becoming more complex, it’s not just the mix of active ingredients that generic drugmakers have to replicate. It’s also the release mechanism.
While making opioid prescriptions harder to get, Indiana’s crackdown helped spur a twofold increase in robberies of pharmacies that exacerbated the state’s standing as No. 1 in the nation for those crimes.
The companies say the drug, now in late-stage clinical trials, could be more effective for pain treatment than opioids—a dangerous category of pain killers that includes hydrocodone, morphine and fentanyl—without the abuse potential of such medications.
The owner and the director of compliance for Noblesville-based Pharmakon Pharmaceuticals Inc. have been charged with multiple criminal counts related to the sale of over-potent compounded painkillers that sickened at least three infants.
America's three insulin manufacturers—Indianapolis-based Eli Lilly and Co., Sanofi and Novo Nordisk—would face fines of $5,000 daily if they fail to provide the data.
In statehouses across the country and in Congress, drugmaker Alkermes is pushing its own addiction treatment while contributing to misconceptions and stigma about other medications used to treat opioid addiction.
The court's unanimous ruling Monday means a loss of billions in sales to makers of original versions of biologic drugs.
